Tag: form

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it entered into a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for potential acquisitions, marketing and other general corporate purposes.

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.

Transaction in Own Shares

$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

REMARKABLY PRESERVED 1962 SHELBY 260 COBRA, ONE OF THE ORIGINAL PROTOTYPE EXAMPLES, OFFERED FROM 36 YEARS OF CHERISHED LONGTERM OWNERSHIP | COBRA JOINED BY MODERN AMERICAN AUTOMOTIVE LEGENDS: HENNESSEY VENOM GT AND THE AMERICAN PERFORMANCE COLLECTION OF DODGE AND CHEVROLET ICONS

AUGA group, AB entity under restructuring (code 126264360, registered office at Konstitucijos pr. 21C, Vilnius, hereinafter referred to as the “Company”), by the initiative and decision of the Board, is convening an Extraordinary General meeting of shareholders on July 14, 2025, at 10:00 a.m., where the Company’s shareholders will vote on the approval of the Company’s draft restructuring plan, hereinafter referred to as the “Meeting”.